Download Now: 7 Unstoppable Growth Engines of India's $10 Trillion Bull Run...
Here is the latest financial fact sheet of MARKSANS PHARMA.. For more details, see the MARKSANS PHARMA. quarterly results and MARKSANS PHARMA. share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 3.2 |
No. of shares | m | 453.16 |
1 Week | % | 0.9 |
1 Month | % | 19.5 |
1 Year | % | 112.1 |
52 week H/L | Rs | 185.4/70.2 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
MARKSANS PHARMA. EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 41 | 27 | 66 | 98 | 74 | |
Low | Rs | 22 | 10 | 13 | 43 | 39 | |
Sales per share (Unadj.) | Rs | 24.4 | 27.7 | 33.6 | 36.4 | 40.9 | |
Earnings per share (Unadj.) | Rs | 2.0 | 3.0 | 5.8 | 4.6 | 5.9 | |
Diluted earnings per share | Rs | 1.8 | 2.7 | 5.3 | 4.1 | 5.9 | |
Cash flow per share (Unadj.) | Rs | 2.5 | 3.6 | 6.7 | 5.7 | 7.0 | |
Dividends per share (Unadj.) | Rs | 0.05 | 0.10 | 0.25 | 0.25 | 0.50 | |
Adj. dividends per share | Rs | 0.05 | 0.09 | 0.23 | 0.23 | 0.50 | |
Avg Dividend yield | % | 0.2 | 0.5 | 0.6 | 0.4 | 0.9 | |
Book value per share (Unadj.) | Rs | 13.3 | 15.5 | 21.7 | 27.1 | 38.5 | |
Adj. book value per share | Rs | 12.0 | 14.0 | 19.6 | 24.5 | 38.5 | |
Shares outstanding (eoy) | m | 409.31 | 409.31 | 409.31 | 409.31 | 453.16 | |
Price / Sales ratio | x | 1.3 | 0.7 | 1.2 | 1.9 | 1.4 | |
Avg P/E ratio | x | 15.9 | 6.2 | 6.8 | 15.4 | 9.7 | |
P/CF ratio (eoy) | x | 12.4 | 5.1 | 5.9 | 12.5 | 8.1 | |
Price / Book Value ratio | x | 2.4 | 1.2 | 1.8 | 2.6 | 1.5 | |
Dividend payout | % | 2.5 | 3.4 | 4.3 | 5.5 | 8.5 | |
Avg Mkt Cap | Rs m | 12,801 | 7,521 | 16,188 | 28,836 | 25,631 | |
Total wages/salary | Rs m | 1,591 | 1,684 | 1,973 | 2,203 | 2,394 |
MARKSANS PHARMA. INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 10,001 | 11,342 | 13,762 | 14,908 | 18,521 | |
Other income | Rs m | 46 | 3 | 67 | 419 | 593 | |
Total revenues | Rs m | 10,047 | 11,345 | 13,829 | 15,327 | 19,115 | |
Gross profit | Rs m | 1,321 | 1,923 | 3,396 | 2,589 | 3,393 | |
Depreciation | Rs m | 228 | 267 | 362 | 448 | 519 | |
Interest | Rs m | 97 | 87 | 80 | 84 | 91 | |
Profit before tax | Rs m | 1,043 | 1,572 | 3,022 | 2,475 | 3,377 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 239 | 364 | 636 | 607 | 723 | |
Profit after tax | Rs m | 804 | 1,208 | 2,385 | 1,868 | 2,653 | |
Gross profit margin | % | 13.2 | 17.0 | 24.7 | 17.4 | 18.3 | |
Effective tax rate | % | 22.9 | 23.2 | 21.1 | 24.5 | 21.4 | |
Net profit margin | % | 8.0 | 10.6 | 17.3 | 12.5 | 14.3 |
MARKSANS PHARMA. BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 5,314 | 5,936 | 9,028 | 12,251 | 16,997 | |
Current liabilities | Rs m | 2,326 | 2,288 | 2,990 | 3,801 | 3,654 | |
Net working cap to sales | % | 29.9 | 32.2 | 43.9 | 56.7 | 72.0 | |
Current ratio | x | 2.3 | 2.6 | 3.0 | 3.2 | 4.7 | |
Inventory Days | Days | 0 | 2 | 1 | 1 | 6 | |
Debtors Days | Days | 64,453,435 | 78,313,067 | 72 | 97 | 82 | |
Net fixed assets | Rs m | 2,710 | 3,084 | 3,252 | 4,350 | 5,246 | |
Share capital | Rs m | 409 | 409 | 409 | 409 | 453 | |
"Free" reserves | Rs m | 5,016 | 5,951 | 8,456 | 10,682 | 16,998 | |
Net worth | Rs m | 5,425 | 6,360 | 8,865 | 11,092 | 17,452 | |
Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
Total assets | Rs m | 8,025 | 9,020 | 12,280 | 16,601 | 22,242 | |
Interest coverage | x | 11.8 | 19.0 | 38.8 | 30.3 | 38.0 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 1.2 | 1.3 | 1.1 | 0.9 | 0.8 | |
Return on assets | % | 11.2 | 14.4 | 20.1 | 11.8 | 12.3 | |
Return on equity | % | 14.8 | 19.0 | 26.9 | 16.8 | 15.2 | |
Return on capital | % | 21.0 | 26.1 | 35.0 | 23.1 | 19.9 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 3.3 | 5.2 | 7.4 | 7.0 | 7.3 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 331 | 586 | 1,014 | 1,040 | 1,348 | |
Fx inflow | Rs m | 4,087 | 4,266 | 5,874 | 6,419 | 6,491 | |
Fx outflow | Rs m | 471 | 737 | 1,014 | 1,040 | 1,348 | |
Net fx | Rs m | 3,616 | 3,529 | 4,860 | 5,379 | 5,143 |
MARKSANS PHARMA. CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 274 | 2,333 | 1,786 | 993 | 2,374 | |
From Investments | Rs m | -135 | -596 | -448 | -844 | -2,592 | |
From Financial Activity | Rs m | -208 | -1,136 | -153 | 795 | 1,978 | |
Net Cashflow | Rs m | -69 | 602 | 1,185 | 944 | 1,760 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Mark Saldanha | COMP SEC: Harshavardhan Panigrahi | YEAR OF INC: 1992 | BSE CODE: 524404 | FV (Rs): 1 | DIV YIELD (%): 0.3 |
Read: MARKSANS PHARMA. 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare MARKSANS PHARMA. With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.